Evaluation of an Intervention to Prevent Falls
ResearchPublished Oct 26, 2016
Researchers followed up on a previously published report of a randomized controlled trial of a fall-prevention intervention. Linking trial data to Medicare claims, they considered whether the intervention reduced health care costs or the frequency of emergency department visits for fall-related injuries. They used these objectively measured outcomes to provide an overall assessment of the intervention's effectiveness.
ResearchPublished Oct 26, 2016
The Office of the Assistant Secretary for Planning and Evaluation (ASPE) in the U.S. Department of Health and Human Services asked the RAND Corporation to evaluate the effectiveness of an intervention designed to prevent falls in the elderly, with a particular focus on fall-related injuries and on health care costs.
Researchers linked data collected during a randomized trial to Medicare enrollment and claims files to compare health care costs and the frequency of fall-related emergency department (ED) visits between treatment and control groups. Using claims from both before and after trial enrollment, they adjusted for baseline differences and used intention-to-treat analyses, thereby overcoming limitations inherent in the outcome data collected during the trial.
The researchers did not find a statistically significant effect of the intervention on costs or on the rate of fall-related ED visits. They estimate that the intervention was associated with an $18-per-month increase (95-percent confidence interval [CI] = –$94 to $130) in total health care spending, an $18-per-month increase (95-percent CI = –$12 to $48) for care directly related to injuries, and a 4-percent increase in the risk of falls (95-percent CI = 26-percent decrease to 43-percent increase).
The researchers concluded that the fall-prevention intervention did not have a substantial effect on health care costs. Although they did not find evidence that the intervention reduced ED visits for fall-related injuries, they cautioned that the study was underpowered for this outcome and that a clinically meaningful effect could have gone undetected.
The research described in this report was sponsored by the Assistant Secretary for Planning and Evaluation (ASPE) and conducted by RAND Health.
This publication is part of the RAND research report series. Research reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND research reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.